Year 2018,
Issue: 4, 349 - 356, 01.12.2018
Abstract
Advanced glycation end products AGEs produced endogenously from non-enzymatic glycation of proteins, lipids and nucleic acids are heterogeneous compounds. In physiological conditions, AGEs may occur in all tissues and body fluids. AGEs are a part of normal metabolism; also, they can be taken to organisms exogenously. AGEs affect the body through two mechanisms. The first mechanism is cross linking of body protein. The second is described as interaction of AGEs with their receptors. Researchers report that there is positive association between the serum concentration of AGEs and type1 and type2 diabetes. This relationship is related to the severity and progression of diabetes complications such as micro vascular and macro vascular complications with an increase in inflammation and endothelial dysfunction markers. Apart from diabetes, effects of AGEs are mentioned in many diseases such as oxidative stress, inflammation, obesity, hypertension, polycystic ovary syndrome and aging process. Although different results were obtained in the studies conducted on healthy individuals; nonetheless, it was found that a low-AGE diet has less of an effect on biochemical markers in healthy individuals compared to diabetic patients. The aim of this review is to discuss roles of dietary AGEs in formation and development of disease and possible effects of AGEs on health
References
- Goldberg T, Cai W, Peppa M, Dardaine V, Baliga BS, Uribarri J, et al. Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc 2004;104:1287-91. [CrossRef]
- Uribarri J, Woodruff S, Goodman S, Cai W, Chen X, Pyzik R, et al. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc 2010;110:911-6. [CrossRef]
- Schmidt AM, Yan SD, Wautier JL, et al. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999;84:489-97.
- Arı N. Yaşlanmada Crosslinkage Teorisi: İlerlemiş Glikasyon Son Ürünlerinin (AGEs) Rolü. Türkiye Klinikleri J Med Sci 2008;28:12-5.
- Poulsen MW, Hedegaard RV, Andersen JM, de Courten B, Bügel S, Nielsen J, et al. Advanced glycation endproducts in food and their effects on health. Food and chemical toxicology: an international journal published for the British Industrial Biological Research Association 2013;60:10-37. [CrossRef]
- Vlassara H, Striker GE. AGE restriction in diabetes mellitus: a paradigm shift. Nat Rev Endocrinol 2011;7:526-39. [CrossRef]
- Sharma C, Kaur A, Thind SS, Singh B, Raina S. Advanced glycation End-products (AGEs): an emerging concern for processed food industries. J Food Sci Technol 2015;52:7561-76. [CrossRef]
- Uribarri J, Cai W, Sandu O, Peppa M, Goldberg T, Vlassara H. Diet- derived advanced glycation end products are major contributors to the body’s AGE pool and induce inflammation in healthy subjects. Annals of the New York Academy of Sciences 2005;1043:461-6. [CrossRef]
- Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia 2001;44:129-46. [CrossRef]
- Ahmed N, Lüthen R, Häussinger D, Sebeková K, Schinzel R, Voelker W, et al. Increased protein glycation in cirrhosis and therapeutic strategies to prevent it. Annals of the New York Academy of Sciences 2005;1043:718-24. [CrossRef]
- Parmaksız İ. Diyabet Komplikasyonlarında İleri Glikasyon Son Ürünleri. Marmara Medical Journal 2011;24:141-8.
- non-enzymatic glycation of proteins. Clin Biochem 2005;38:103-15. [CrossRef]
- Hartog JW, Voors AA, Bakker SJ, Smit AJ, van Veldhuisen DJ. Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications. European journal of heart failure 2007;9:1146-55. [CrossRef]
- Coughlan MT, Yap FY, Tong DC, Andrikopoulos S, Gasser A, Thallas- Bonke V, et al. Advanced glycation end products are direct modulators of beta-cell function. Diabetes 2011;60:2523-32. [CrossRef]
- Chuyen NV, Arai H, Nakanishi T, Utsunomiya N. Are food advanced glycation end products toxic in biological systems? Annals of the New York Academy of Sciences 2005;1043:467-73. [CrossRef]
- Sandu O, Song K, Cai W, Zheng F, Uribarri J, Vlassara H. Insulin resistance and type 2 diabetes in high-fat-fed mice are linked to high glycotoxin intake. Diabetes 2005;54:2314-9.
- Cai W, He JC, Zhu L, Chen X, Zheng F, Striker GE, et al. Oral glycotoxins determine the effects of calorie restriction on oxidant stress, age- related diseases, and lifespan. The American journal of pathology 2008;173:327-36. [CrossRef]
- Cai W, Ramdas M, Zhu L, Chen X, Striker GE, Vlassara H. Oral advanced glycation endproducts (AGEs) promote insulin resistance and diabetes by depleting the antioxidant defenses AGE receptor-1 and sirtuin 1. Proc Natl Acad Sci USA 2012;109:15888-93. [CrossRef]
- Hwang JS, Shin CH, Yang SW. Clinical implications of N epsilon- (carboxymethyl)lysine, advanced glycation end product, in children and adolescents with type 1 diabetes. Diabetes Obes Metab 2005;7:263-7. [CrossRef]
- Aso Y, Inukai T, Tayama K, Takemura Y. Serum concentrations of advanced glycation endproducts are associated with the development of atherosclerosis as well as diabetic microangiopathy in patients with type 2 diabetes. Acta Diabetol 2000;37:87-92.
- Busch M, Franke S, Wolf G, Brandstädt A, Ott U, Gerth J, et al. The advanced glycation end product N(epsilon)-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension. American journal of kidney diseases: the official journal of the National Kidney Foundation 2006;48:571-9. [CrossRef]
- Chao PC, Huang CN, Hsu CC, Yin MC, Guo YR. Association of dietary AGEs with circulating AGEs, glycated LDL, IL-1alpha and MCP-1 levels in type 2 diabetic patients. Eur J Nutr 2010;49:429-34. [CrossRef]
- Vlassara H, Cai W, Crandall J, Goldberg T, Oberstein R, Dardaine V, et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proceedings of the National Academy of Sciences of the United States of America 2002;99:15596-601. [CrossRef]
- Uribarri J, Cai W, Ramdas M, Goodman S, Pyzik R, Chen X, et al. Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and SIRT1. Diabetes Care 2011;34:1610-6. [CrossRef]
- Kratochvilova M, Zakiyanov O, Kalousová M, Kříha V, Zima T, Tesař V. Associations of serum levels of advanced glycation end products with nutrition markers and anemia in patients with chronic kidney disease. Renal failure 2011;33:131-7. [CrossRef]
- Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Ueda Y, Suzuki T, et al. Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients. Metabolism: clinical and experimental 2009;58:1624-8. [CrossRef]
- Peppa M, Uribarri J, Cai W, Lu M, Vlassara H. Glycoxidation and inflammation in renal failure patients. American journal of kidney diseases: the official journal of the National Kidney Foundation 2004;43:690-5.
- Vlassara H, Cai W, Goodman S, Pyzik R, Yong A, Chen X, et al. Protection against loss of innate defenses in adulthood by low advanced glycation end products (AGE) intake: role of the antiinflammatory AGE receptor-1. The Journal of clinical endocrinology and metabolism 2009;94:4483-91. [CrossRef]
- Suji G, Sivakami S. Glucose, glycation and aging. Biogerontology 2004;5: 365-73. [CrossRef]
- Cai W, He JC, Zhu L, Chen X, Wallenstein S, Striker GE, et al. Reduced oxidant stress and extended lifespan in mice exposed to a low glycotoxin diet: association with increased AGER1 expression. The American journal of pathology 2007;170:1893-902. [CrossRef]
- Shannon M, Wang Y. Polycystic ovary syndrome: a common but often unrecognized condition. J Midwifery Womens Health 2012;57:221- 30. [CrossRef]
- Diamanti-Kandarakis E, Piperi C, Patsouris E, Korkolopoulou P, Panidis D, Pawelczyk L, et al. Immunohistochemical localization of advanced glycation end-products (AGEs) and their receptor (RAGE) in polycystic and normal ovaries. Histochem Cell Biol 2007;127:581- 9. [CrossRef]
- Basta G. Receptor for advanced glycation endproducts and atherosclerosis: From basic mechanisms to clinical implications. Atherosclerosis 2008;196:9-21. [CrossRef]
- Tantalaki E, Piperi C2 Livadas S, Kollias A, Adamopoulos C, Koulouri A, et al. Impact of dietary modification of advanced glycation end products (AGEs) on the hormonal and metabolic profile of women with polycystic ovary syndrome (PCOS). Hormones (Athens) 2014;13:65-73.
- Chatzigeorgiou A, Kandaraki E, Piperi C, Livadas S, Papavassiliou AG, Koutsilieris M, et al. Dietary glycotoxins affect scavenger receptor expression and the hormonal profile of female rats. J Endocrinol 2013;218:331-7. [CrossRef]
- Garg D, Merhi Z. Advanced Glycation End Products: Link between Diet and Ovulatory Dysfunction in PCOS? Nutrients 2015;7:10129- 44. [CrossRef]
- Uribarri J, Cai W, Peppa M, et al. Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging. J Gerontol A Biol Sci Med Sci 2007;62:427-33.
- Krajcovicova-Kudlackova M, Sebeková K, Schinzel R, Klvanová J. Advanced glycation end products and nutrition. Physiol Res 2002;51:313-6.
- Sebekova K, Somoza V, Jarcusková M, Heidland A, Podracká L. Plasma advanced glycation end products are decreased in obese children compared with lean controls. Int J Pediatr Obes 2009;4:112- 8. [CrossRef]
Year 2018,
Issue: 4, 349 - 356, 01.12.2018
Abstract
İleri glikasyon son ürünleri AGE’ler proteinler, lipitler ve nükleik asitlerin nonenzimatik glikasyonundan endojen olarak üretilen heterojen bileşiklerdir. Fizyolojik koşullarda tüm dokularda ve vücut sıvılarında AGE’ler oluşabilmektedir. Normal metabolizmanın bir parçası olan AGE’ler, eksojen olarak da organizmaya alınabilmektedir. AGE’lerin iki ayrı mekanizmayla vücudu etkilediği açıklanmaktadır. Bu mekanizmalardan ilki, vücut proteinlerinin çapraz bağlanması, ikincisi ise AGE’lerin reseptörleri ile etkileşimidir. Araştırmacılar, AGE’lerin serum konsantrasyonu ile tip 1 ve tip 2 diyabet arasında pozitif ilişki olduğunu bildirmektedir. Bu ilişki diyabetin özellikle mikrovasküler ve makrovasküler komplikasyonlar, inflamasyon ve endotel disfonksiyon belirteçlerindeki artış gibi komplikasyonlarının şiddeti ve ilerlemesi ile ilgilidir. Diyabetin yanı sıra oksidatif stres, inflamasyon, obezite, hipertansiyon, polikistik over sendromu gibi birçok hastalık ve yaşlanma sürecinde AGE’lerin etkilerinden bahsedilmektedir. Sağlıklı bireyler üzerinde yapılan çalışmalarda farklı sonuçlar elde edilse de düşük AGE içerikli diyetin, diyabetli hastalara göre sağlıklı bireylerde daha az biyokimyasal belirteci etkilediği saptanmıştır. Bu derlemede amaç, diyet kaynaklı AGE’lerin hastalıkların oluşumu ve gelişmesindeki rolleri ile sağlık üzerine muhtemel etkilerini tartışmaktır
References
- Goldberg T, Cai W, Peppa M, Dardaine V, Baliga BS, Uribarri J, et al. Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc 2004;104:1287-91. [CrossRef]
- Uribarri J, Woodruff S, Goodman S, Cai W, Chen X, Pyzik R, et al. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc 2010;110:911-6. [CrossRef]
- Schmidt AM, Yan SD, Wautier JL, et al. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999;84:489-97.
- Arı N. Yaşlanmada Crosslinkage Teorisi: İlerlemiş Glikasyon Son Ürünlerinin (AGEs) Rolü. Türkiye Klinikleri J Med Sci 2008;28:12-5.
- Poulsen MW, Hedegaard RV, Andersen JM, de Courten B, Bügel S, Nielsen J, et al. Advanced glycation endproducts in food and their effects on health. Food and chemical toxicology: an international journal published for the British Industrial Biological Research Association 2013;60:10-37. [CrossRef]
- Vlassara H, Striker GE. AGE restriction in diabetes mellitus: a paradigm shift. Nat Rev Endocrinol 2011;7:526-39. [CrossRef]
- Sharma C, Kaur A, Thind SS, Singh B, Raina S. Advanced glycation End-products (AGEs): an emerging concern for processed food industries. J Food Sci Technol 2015;52:7561-76. [CrossRef]
- Uribarri J, Cai W, Sandu O, Peppa M, Goldberg T, Vlassara H. Diet- derived advanced glycation end products are major contributors to the body’s AGE pool and induce inflammation in healthy subjects. Annals of the New York Academy of Sciences 2005;1043:461-6. [CrossRef]
- Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia 2001;44:129-46. [CrossRef]
- Ahmed N, Lüthen R, Häussinger D, Sebeková K, Schinzel R, Voelker W, et al. Increased protein glycation in cirrhosis and therapeutic strategies to prevent it. Annals of the New York Academy of Sciences 2005;1043:718-24. [CrossRef]
- Parmaksız İ. Diyabet Komplikasyonlarında İleri Glikasyon Son Ürünleri. Marmara Medical Journal 2011;24:141-8.
- non-enzymatic glycation of proteins. Clin Biochem 2005;38:103-15. [CrossRef]
- Hartog JW, Voors AA, Bakker SJ, Smit AJ, van Veldhuisen DJ. Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications. European journal of heart failure 2007;9:1146-55. [CrossRef]
- Coughlan MT, Yap FY, Tong DC, Andrikopoulos S, Gasser A, Thallas- Bonke V, et al. Advanced glycation end products are direct modulators of beta-cell function. Diabetes 2011;60:2523-32. [CrossRef]
- Chuyen NV, Arai H, Nakanishi T, Utsunomiya N. Are food advanced glycation end products toxic in biological systems? Annals of the New York Academy of Sciences 2005;1043:467-73. [CrossRef]
- Sandu O, Song K, Cai W, Zheng F, Uribarri J, Vlassara H. Insulin resistance and type 2 diabetes in high-fat-fed mice are linked to high glycotoxin intake. Diabetes 2005;54:2314-9.
- Cai W, He JC, Zhu L, Chen X, Zheng F, Striker GE, et al. Oral glycotoxins determine the effects of calorie restriction on oxidant stress, age- related diseases, and lifespan. The American journal of pathology 2008;173:327-36. [CrossRef]
- Cai W, Ramdas M, Zhu L, Chen X, Striker GE, Vlassara H. Oral advanced glycation endproducts (AGEs) promote insulin resistance and diabetes by depleting the antioxidant defenses AGE receptor-1 and sirtuin 1. Proc Natl Acad Sci USA 2012;109:15888-93. [CrossRef]
- Hwang JS, Shin CH, Yang SW. Clinical implications of N epsilon- (carboxymethyl)lysine, advanced glycation end product, in children and adolescents with type 1 diabetes. Diabetes Obes Metab 2005;7:263-7. [CrossRef]
- Aso Y, Inukai T, Tayama K, Takemura Y. Serum concentrations of advanced glycation endproducts are associated with the development of atherosclerosis as well as diabetic microangiopathy in patients with type 2 diabetes. Acta Diabetol 2000;37:87-92.
- Busch M, Franke S, Wolf G, Brandstädt A, Ott U, Gerth J, et al. The advanced glycation end product N(epsilon)-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension. American journal of kidney diseases: the official journal of the National Kidney Foundation 2006;48:571-9. [CrossRef]
- Chao PC, Huang CN, Hsu CC, Yin MC, Guo YR. Association of dietary AGEs with circulating AGEs, glycated LDL, IL-1alpha and MCP-1 levels in type 2 diabetic patients. Eur J Nutr 2010;49:429-34. [CrossRef]
- Vlassara H, Cai W, Crandall J, Goldberg T, Oberstein R, Dardaine V, et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proceedings of the National Academy of Sciences of the United States of America 2002;99:15596-601. [CrossRef]
- Uribarri J, Cai W, Ramdas M, Goodman S, Pyzik R, Chen X, et al. Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and SIRT1. Diabetes Care 2011;34:1610-6. [CrossRef]
- Kratochvilova M, Zakiyanov O, Kalousová M, Kříha V, Zima T, Tesař V. Associations of serum levels of advanced glycation end products with nutrition markers and anemia in patients with chronic kidney disease. Renal failure 2011;33:131-7. [CrossRef]
- Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Ueda Y, Suzuki T, et al. Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients. Metabolism: clinical and experimental 2009;58:1624-8. [CrossRef]
- Peppa M, Uribarri J, Cai W, Lu M, Vlassara H. Glycoxidation and inflammation in renal failure patients. American journal of kidney diseases: the official journal of the National Kidney Foundation 2004;43:690-5.
- Vlassara H, Cai W, Goodman S, Pyzik R, Yong A, Chen X, et al. Protection against loss of innate defenses in adulthood by low advanced glycation end products (AGE) intake: role of the antiinflammatory AGE receptor-1. The Journal of clinical endocrinology and metabolism 2009;94:4483-91. [CrossRef]
- Suji G, Sivakami S. Glucose, glycation and aging. Biogerontology 2004;5: 365-73. [CrossRef]
- Cai W, He JC, Zhu L, Chen X, Wallenstein S, Striker GE, et al. Reduced oxidant stress and extended lifespan in mice exposed to a low glycotoxin diet: association with increased AGER1 expression. The American journal of pathology 2007;170:1893-902. [CrossRef]
- Shannon M, Wang Y. Polycystic ovary syndrome: a common but often unrecognized condition. J Midwifery Womens Health 2012;57:221- 30. [CrossRef]
- Diamanti-Kandarakis E, Piperi C, Patsouris E, Korkolopoulou P, Panidis D, Pawelczyk L, et al. Immunohistochemical localization of advanced glycation end-products (AGEs) and their receptor (RAGE) in polycystic and normal ovaries. Histochem Cell Biol 2007;127:581- 9. [CrossRef]
- Basta G. Receptor for advanced glycation endproducts and atherosclerosis: From basic mechanisms to clinical implications. Atherosclerosis 2008;196:9-21. [CrossRef]
- Tantalaki E, Piperi C2 Livadas S, Kollias A, Adamopoulos C, Koulouri A, et al. Impact of dietary modification of advanced glycation end products (AGEs) on the hormonal and metabolic profile of women with polycystic ovary syndrome (PCOS). Hormones (Athens) 2014;13:65-73.
- Chatzigeorgiou A, Kandaraki E, Piperi C, Livadas S, Papavassiliou AG, Koutsilieris M, et al. Dietary glycotoxins affect scavenger receptor expression and the hormonal profile of female rats. J Endocrinol 2013;218:331-7. [CrossRef]
- Garg D, Merhi Z. Advanced Glycation End Products: Link between Diet and Ovulatory Dysfunction in PCOS? Nutrients 2015;7:10129- 44. [CrossRef]
- Uribarri J, Cai W, Peppa M, et al. Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging. J Gerontol A Biol Sci Med Sci 2007;62:427-33.
- Krajcovicova-Kudlackova M, Sebeková K, Schinzel R, Klvanová J. Advanced glycation end products and nutrition. Physiol Res 2002;51:313-6.
- Sebekova K, Somoza V, Jarcusková M, Heidland A, Podracká L. Plasma advanced glycation end products are decreased in obese children compared with lean controls. Int J Pediatr Obes 2009;4:112- 8. [CrossRef]
There are 39 citations in total.
Details
| Primary Language | Turkish |
|---|---|
| Journal Section | Research Article |
| Authors | |
| Publication Date | December 1, 2018 |
| Published in Issue | Year 2018Issue: 4 |